Sept. 19 Preclinical Quick Takes: Celsius' single-cell analysis; plus Merck's RSV therapy, glial cell transplant and methylation profiles for tumors

Celsius gets three single-cell analysis partners
Through separate deals, Celsius Therapeutics Inc. partnered with the Parker Institute for Cancer Immunotherapy, Institut Gustave-Roussy and University Health Network to apply its single-cell genomics platform, which includes machine-learning algorithms, to tissue samples from patients receiving checkpoint inhibitor therapies.

Read the full 446 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE